Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
Prostatic Neoplasms · Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 195 (final count)
- Started
- Sep 7, 2021
- Main results expected
- Nov 24, 2023
- Fully finished
- Nov 24, 2023
- Results posted
- Dec 18, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Patient-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity
Measured over: vidoflufolastat (18F)7 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from vidoflufolastat (18F) scan
Region-level Specificity of Vidoflufolastat (18F) - % Specificity
Measured over: vidoflufolastat (18F) PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from vidoflufolastat (18F) scan
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04838626 · record last updated 2025-10-07 · checked 2026-11-09 15:47 UTC